Published in J Clin Pharmacol on February 01, 2001
Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety. Br J Pharmacol (2010) 1.15
Clinically significant drug-drug interactions involving opioid analgesics used for pain treatment in patients with cancer: a systematic review. Drug Des Devel Ther (2015) 0.78
An unusual case of serotonin syndrome with oxycodone and citalopram. Case Rep Oncol Med (2012) 0.76
Studies on the properties and mode of action of the purified regulatory subunit of bovine heart adenosine 3':5'-monophosphate-dependent protein kinase. J Biol Chem (1978) 2.32
Regulatory mechanisms in the control of protein kinases. CRC Crit Rev Biochem (1982) 2.20
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Sex hormones prolong the QT interval and downregulate potassium channel expression in the rabbit heart. Circulation (1996) 2.13
Tolerance to the humoral and hemodynamic effects of caffeine in man. J Clin Invest (1981) 2.03
Drug-induced QT prolongation in women during the menstrual cycle. JAMA (2001) 1.87
Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. Eur Heart J (1995) 1.76
Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. Am Heart J (1986) 1.74
Electrophysiologic features of torsades de pointes: insights from a new isolated rabbit heart model. J Cardiovasc Electrophysiol (1997) 1.74
Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin. Clin Pharmacol Ther (1992) 1.68
Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: studies with cDNA and oligonucleotide expression arrays. J Pharmacol Exp Ther (2001) 1.64
Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob Agents Chemother (2001) 1.58
Simultaneous analysis of dapsone and monoacetyldapsone employing high performance liquid chromatography: a rapid method for determination of acetylator phenotype. Br J Clin Pharmacol (1978) 1.57
Cardiac actions of erythromycin: influence of female sex. JAMA (1998) 1.53
Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos (1997) 1.52
A SNP in steroid receptor coactivator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in bone. Mol Endocrinol (2011) 1.45
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J (2009) 1.43
Pharmacies and prevention of potentially fatal drug interactions. JAMA (1996) 1.42
Treatment of tobacco dependence: innovative regulatory approaches to reduce death and disease: preface. Food Drug Law J (1998) 1.39
Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants. Pharmacogenetics (2001) 1.39
Estrogen receptor genotypes, menopausal status, and the lipid effects of tamoxifen. Clin Pharmacol Ther (2007) 1.39
Gender difference in the cycle length-dependent QT and potassium currents in rabbits. J Pharmacol Exp Ther (1998) 1.38
Effect of acetylator phenotype on the rate at which procainamide induces antinuclear antibodies and the lupus syndrome. N Engl J Med (1978) 1.37
The star-allele nomenclature: retooling for translational genomics. Clin Pharmacol Ther (2007) 1.35
Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics (1999) 1.33
The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther (1995) 1.31
Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide. Am J Cardiol (1981) 1.28
Gadolinium decreases stretch-induced vulnerability to atrial fibrillation. Circulation (2000) 1.23
Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective. Clin Pharmacol Ther (2013) 1.22
Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. Circulation (1987) 1.22
Female gender as a risk factor for drug-induced cardiac arrhythmias: evaluation of clinical and experimental evidence. J Womens Health (1998) 1.21
Inhibition of IL-12 production by thalidomide. J Immunol (1997) 1.20
Drug therapy. Flecainide. N Engl J Med (1986) 1.19
Chlorpheniramine plasma concentration and histamine H1-receptor occupancy. Clin Pharmacol Ther (1995) 1.15
In vivo and in vitro phosphorylation of rat liver fructose-1,6-bisphosphatase. Proc Natl Acad Sci U S A (1977) 1.15
Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos (1999) 1.14
Drug interactions, cardiac toxicity, and terfenadine: from bench to clinic? J Clin Psychopharmacol (1996) 1.11
The use of imaging in the early development of neuropharmacological drugs: a survey of approved NDAs. Clin Pharmacol Ther (2007) 1.11
Greater quinidine-induced QTc interval prolongation in women. Clin Pharmacol Ther (2000) 1.11
In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6. Br J Clin Pharmacol (2000) 1.08
Enhancing race-based prescribing precision with pharmacogenomics. Clin Pharmacol Ther (2007) 1.08
The clinical value of FDA class C drugs approved from 1981 to 1988. Clin Pharmacol Ther (1992) 1.07
Clinical pharmacology of propafenone: pharmacokinetics, metabolism and concentration-response relations. Am J Cardiol (1984) 1.07
Suppression of ventricular ectopic depolarizations by tocainide. Circulation (1977) 1.06
Studies on functional domains of the regulatory subunit of bovine heart adenosine 3':5'-monophosphate-dependent protein kinase. J Biol Chem (1980) 1.05
Suppression of chronic ventricular arrhythmias with propranolol. Circulation (1979) 1.04
Stereoselective disposition and pharmacologic activity of propafenone enantiomers. Circulation (1989) 1.04
The gastroprokinetic and antiemetic drug metoclopramide is a substrate and inhibitor of cytochrome P450 2D6. Drug Metab Dispos (2002) 1.03
Biological sex analysis in clinical research. J Womens Health Gend Based Med (2000) 1.02
Influence of genetic polymorphism on the metabolism and disposition of encainide in man. J Pharmacol Exp Ther (1984) 1.02
Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. Clin Pharmacol Ther (2011) 1.00
Normal distribution of acetylation phenotypes in systemic lupus erythematosus. Arthritis Rheum (1978) 1.00
Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium. Clin Pharmacol Ther (2009) 1.00
Mechanism of cardiotoxicity of halofantrine. Clin Pharmacol Ther (2000) 1.00
Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study. Br J Cancer (2010) 0.99
Altered distribution of debrisoquine oxidation phenotypes in patients with systemic lupus erythematosus. Arthritis Rheum (1986) 0.99
Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther (1998) 0.99
The electrocardiographic effects of cetirizine in normal subjects. Clin Pharmacol Ther (1994) 0.98
Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther (1996) 0.98
N-acetylation phenotype and genotype and risk of bladder cancer in benzidine-exposed workers. Carcinogenesis (1993) 0.98
The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol (1995) 0.97
Mexiletine in the treatment of resistant ventricular arrhythmias: enhancement of efficacy and reduction of dose-related side effects by combination with quinidine. Circulation (1983) 0.96
The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N Engl J Med (1990) 0.96
Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects. Clin Pharmacol Ther (2000) 0.96
Sotalol. N Engl J Med (1994) 0.95
The Coalition Against Major Diseases: developing tools for an integrated drug development process for Alzheimer's and Parkinson's diseases. Clin Pharmacol Ther (2009) 0.94
The Cardiac Arrhythmia Suppression Trial: first CAST ... then CAST-II. J Am Coll Cardiol (1992) 0.94
Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals. J Clin Invest (1984) 0.93
Concentration-dependent pharmacologic properties of sotalol. Am J Cardiol (1986) 0.93
Salivary analysis for determination of dextromethorphan metabolic phenotype. Clin Pharmacol Ther (1991) 0.92
Studies on the structure and mechanism of activation of the guanosine 3':5'-monophosphate-dependent protein kinase. J Biol Chem (1978) 0.92
Ticlopidine inhibition of phenytoin metabolism mediated by potent inhibition of CYP2C19. Clin Pharmacol Ther (1997) 0.92
Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther (1999) 0.92
Total suppression of ventricular arrhythmias by encainide. Pharmacokinetic and electrocardiographic characteristics. N Engl J Med (1980) 0.91
Pharmacogenetics in the treatment of breast cancer. Pharmacogenomics J (2004) 0.91
Formal education about medication errors in internal medicine clerkships. JAMA (2001) 0.91
Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. J Pharmacol Exp Ther (1989) 0.91
Suppression of ventricular arrhythmias in man by d-propranolol independent of beta-adrenergic receptor blockade. J Clin Invest (1990) 0.90
Co-inheritance of the polymorphic metabolism of encainide and debrisoquin. Clin Pharmacol Ther (1986) 0.90
Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide. Am J Cardiol (1980) 0.90
Antiarrhythmic effects of a lidocaine congener, tocainide, 2-amino-2',6'-propionoxylidide, in man. Clin Pharmacol Ther (1976) 0.89
Correlation between N-acetyltransferase activity and NAT2 genotype in Chinese males. Pharmacogenetics (1993) 0.89
Investigation of the subcellular distribution of cyclic-AMP phosphodiesterase in rat hepatocytes, using a rapid immunological procedure for the isolation of plasma membrane. Biochim Biophys Acta (1979) 0.89
Electrophysiologic actions of high plasma concentrations of propranolol in human subjects. J Am Coll Cardiol (1983) 0.89
Pharmacoepidemiologic and in vitro evaluation of potential drug-drug interactions of sulfonylureas with fibrates and statins. Br J Clin Pharmacol (2014) 0.89
The need for translational research on drug-drug interactions. Clin Pharmacol Ther (2012) 0.88
Female gender is a risk factor for torsades de pointes in an in vitro animal model. J Cardiovasc Pharmacol (1999) 0.88
Metabolism of procainamide to a hydroxylamine by rat and human hepatic microsomes. Drug Metab Dispos (1984) 0.88
Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy. Br J Cancer (2009) 0.88
Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect. Br J Clin Pharmacol (1989) 0.88
Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. Clin Pharmacol Ther (1998) 0.87
Terfenadine increases the QT interval in isolated guinea pig heart. J Cardiovasc Pharmacol (1995) 0.87
The implications of procainamide metabolism to its induction of lupus. Arthritis Rheum (1981) 0.87
Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects. Br J Cancer (2013) 0.87
Olanzapine-induced rhabdomyolysis. Ann Pharmacother (2001) 0.86
Genome-wide discovery of genetic variants affecting tamoxifen sensitivity and their clinical and functional validation. Ann Oncol (2013) 0.86